Results 71 to 80 of about 1,911 (163)

Cutaneous Rosai-Dorfman-Destombes disease: the diagnostic value of the yellow island sign. [PDF]

Oxf Med Case Reports
El Maati M, Sassine FZ, Rimani M, Benzekri L, Ismaili N.   +4 more
europepmc   +1 more source

Prominent emperipolesis in breast lesion: A diagnostic challenge

Cytojournal, 2023
Sahai, Rishabh, Singh, Divya, Shrivastava, Vikas, Singh, Mukul, Gupta, Brijnandan   +4 more
openaire   +2 more sources

Cutaneous Rosai-Dorfman Disease - A Rare Non-Langerhans Cell Histiocytosis

JK Science
Cutaneous Rosai-Dorfman disease is classified as non-Langerhans cell histiocytosis. It is a benign lymphoproliferative disorder involving only skin and subcutaneous tissue, which is rare and not well documented.
Afthab Jameela Wahab, S. Athilakshmi, Nivvedhetha S   +2 more
doaj  

Cutaneous Rosai-Dorfman Disease Misdiagnosed as Granulomatous Dermatitis: A Diagnostic Pitfall. [PDF]

Cureus
Naidnur S, Hedrick J, Marupudi S, Asbury K, Maedo K, Gammon B, Lin R.   +6 more
europepmc   +1 more source

Neutrophilic emperipolesis in micropapillary carcinoma breast

The Breast Journal, 2020
Manoj Gopal Madakshira, Uma Nahar Saikia
openaire   +2 more sources

Rosai-Dorfman disease presenting as isolated cervical lymphadenopathy in a young adult: A case report. [PDF]

Radiol Case Rep
Rguyeg A, Boutahar M, Lachkar A.
europepmc   +1 more source

Extranodal Rosai-Dorfman Disease Presenting as a Pancreatic Mass Associated With Superior Mesenteric Artery Thrombosis. [PDF]

ACG Case Rep J
Albares P, Bean S, Jowell P, Johnson A.
europepmc   +1 more source

Extranodal Rosai-Dorfman disease with bilateral renal involvement: A diagnostic challenge. [PDF]

Radiol Case Rep
Nazir N, Ashraf A, Israr F, Rehman AU, Siddique K.   +4 more
europepmc   +1 more source

Case Report: ALK-positive histiocytosis presenting as an adrenal mass: a diagnostic trap due to unusual morphology. [PDF]

Front Oncol
Ma W, Zhou S, Lu J, Wei H, Huang Y.
europepmc   +1 more source

Rosai-Dorfman disease with <i>MAP2K1</i> mutation: therapeutic response to MEK inhibition after failure of conventional therapy. [PDF]

Oxf Med Case Reports
Barbosa Carvalho do Carmo C, Potiguara de Sousa AL, de Souza Alves Glória GH, Serpa Andrade Borges I, Cervantes Sartorelli A, Nonino A.   +5 more
europepmc   +1 more source